Arvinas, Inc. (NASDAQ:ARVN) Receives $63.50 Average Price Target from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have received an average rating of “Moderate Buy” from the fifteen analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $63.50.

Several brokerages have commented on ARVN. Oppenheimer lowered their target price on Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. BMO Capital Markets lowered their price objective on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. HC Wainwright restated a “buy” rating and issued a $87.00 target price on shares of Arvinas in a research report on Wednesday, December 11th. Guggenheim reiterated a “buy” rating on shares of Arvinas in a report on Thursday, December 12th. Finally, Stephens assumed coverage on Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 price objective on the stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new stake in shares of Arvinas during the third quarter worth $39,000. KBC Group NV grew its holdings in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares during the period. Amalgamated Bank raised its position in shares of Arvinas by 29.6% in the 2nd quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock worth $59,000 after acquiring an additional 508 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after purchasing an additional 440 shares during the period. Finally, Quantbot Technologies LP boosted its position in shares of Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares in the last quarter. Institutional investors own 95.19% of the company’s stock.

Arvinas Price Performance

Shares of NASDAQ:ARVN opened at $18.21 on Tuesday. Arvinas has a 1 year low of $17.08 and a 1 year high of $53.08. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -3.90 and a beta of 1.87. The company’s 50 day simple moving average is $20.79 and its 200 day simple moving average is $24.25.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.20. The business had revenue of $102.40 million during the quarter, compared to the consensus estimate of $60.56 million. During the same quarter in the previous year, the business posted ($1.18) EPS. The company’s revenue for the quarter was up 196.0% on a year-over-year basis. As a group, analysts anticipate that Arvinas will post -3.22 EPS for the current fiscal year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.